Difference between revisions of "Team:CGU Taiwan/Entrepreneurship"

(Prototype team page)
 
 
(36 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
{{CGU_Taiwan}}
 
 
<html>
 
<html>
 +
<meta http-equiv="X-UA-Compatible" content="IE=edge">
 +
<style>
 +
        #sideMenu
 +
        {
 +
        display:none; /* Disable the display of the annoying side main menu*/
 +
        }
 +
       
 +
        #top_title
 +
        {
 +
        display:none; /* Disable the annoying title*/
 +
        }
  
 +
#content { padding:0px; width:100%; margin-left:0%; margin-right:0%;}
 +
</style>
 +
<!-- ////////////////////// START  TOP HEADER /////////////////////// -->
 +
<head>
 +
<style>
 +
body {
 +
  background-color:white;
 +
}
 +
.top {
 +
  position: absolute;
 +
  top: -1%;
 +
  left: 0%;
 +
  width: 100%;
 +
  box-sizing:border-box;
 +
  height: 115px;
 +
  font-family: Corbel;
 +
  overflow:visible;
 +
  z-index: +1;
 +
}
 +
.mid {
 +
  position: absolute;
 +
  left: 5%;
 +
  width: 80%;
 +
  height: 100%;
 +
  font-family: Corbel;
 +
}
 +
.headline {
 +
  color: #ffe;
 +
  text-align: center;
 +
  padding-top: 40px;
 +
  padding-bottom: 60px;
 +
}
 +
.header-subnav  {
 +
  background: #0D014D;
 +
  width: 100%;
 +
  position: absolute;
 +
  text-align: center;
 +
  margin: 0 auto;
 +
  top: 116%;
 +
  left: 0%;
 +
  font-family: Corbel;
 +
  z-index:-1;
 +
}
 +
.header-subnav li {
 +
  float: none;
 +
  display: inline-block;
 +
}
 +
.header-subnav li a {
 +
  padding: 15px 1rem;
 +
  font-size: 13px;
 +
  text-decoration: none;
 +
  color: #ffe;
 +
  text-transform: uppercase;
 +
  display: block;
 +
  font-weight: bold;
 +
  letter-spacing: 1px;
 +
  transition: all 0.35s ease-in-out;
 +
  border-radius: 4px;
 +
}
 +
.header-subnav li a.is-active {
 +
  background: rgba(250, 250, 250, 0.15);
 +
}
 +
.header-subnav li a:hover {
 +
  background: #d0d0d0;
 +
  color: #140731;
 +
  transition: all 0.35s ease-in-out;
 +
}
 +
.fixed1 {
 +
  position: fixed;
 +
  top: 13px;
 +
}
 +
.circle {
 +
  position:absolute;
 +
  left: 85.5%;
 +
  top: 70%;
 +
  width: 180px;
 +
  height: 180px;
 +
  background: #0D014D;
 +
  -moz-border-radius: 90px;
 +
  -webkit-border-radius: 90px;
 +
  border-radius: 90px;
 +
}
 +
.left {
 +
  padding: 10px;
 +
  height:200px;
 +
  border-color:#140731;
 +
  border-radius:8px;
 +
  border-width:2px;
 +
  border-style:solid;
 +
  position: absolute;
 +
  left: 25px;
 +
  top: 230px;
 +
  font-family: Corbel;
 +
  background: rgba(250, 250, 250, 0.15);
 +
  width: 170px;
 +
  z-index:+1;
 +
}
  
−
<div class="column full_size judges-will-not-evaluate">
+
.left-tab {
−
<h3>★  ALERT! </h3>
+
  background-color: rgba(250, 250, 250, 0.1);
−
<p>This page is used by the judges to evaluate your team for the <a href="https://2016.igem.org/Judging/Awards#SpecialPrizes">Best Supporting Entrepreneurship award</a>. </p>
+
  display: block;
 +
  font-size: 20px;
 +
  color: #0D014D;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: 40px;
 +
  padding-left: 5px;
 +
  padding-top: 5px;
 +
  padding-bottom: 5px;
 +
  z-index:+1;
 +
}
 +
.left-tab:hover {
 +
  background-color: #FF8800;
 +
  color: #0D014D;
 +
  font-size: 20px;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: -20px;
 +
  padding-left: 5px;
 +
  border-radius: 4px;
 +
}
 +
.fixed2 {
 +
  position: fixed;
 +
  top: 68px;
 +
}
  
 +
.button {
 +
  background-color: rgba(250, 250, 250, 0.1);
 +
  display: block;
 +
  font-size: 16px;
 +
  color: #140731;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: 40px;
 +
  padding-left: 5px;
 +
  padding-top: 5px;
 +
  padding-bottom: 5px;
 +
  z-index:+1;
 +
}
 +
.wrapper {
 +
  background: white;
 +
  width: 900px;
 +
  height: 500px;
 +
  border-radius: 5px;
 +
  position: relative;
 +
  overflow: hidden;
 +
  backface-visibility: hidden;
 +
}
  
−
<p> Delete this box in order to be evaluated for this medal. See more information at <a href="https://2016.igem.org/Judging/Pages_for_Awards/Instructions"> Instructions for Pages for awards</a>.</p>
+
.frame{
−
</div>
+
  background: transparent;
 +
  width: 600px;
 +
  height: 500px;
 +
  border-top: solid 45px white;
 +
  border-right: solid 5px white;
 +
  border-bottom: solid 5px white;
 +
  border-left: solid 5px white;
 +
  position: absolute;
 +
  z-index: 1;
 +
}
  
 +
input[type='radio'] {
 +
  -webkit-appearance: none;
 +
  background: #FF8800;
 +
  border-radius: 4px;
 +
  border-color: #FF8800;
 +
  width: 119px;
 +
  height: 35px;
 +
  margin: 5px 0 5px 5px;
 +
  background-size: 225px 70px;
 +
  position: relative;
 +
  left: 200px;
 +
  float: left;
 +
  display: inline;
 +
  top: 0;
 +
  border-radius: 5px;
 +
  z-index: 99999;
 +
  cursor: pointer;
 +
}
  
 +
input[type='radio']:before{
 +
  content: attr(data-tooltip);
 +
  color: black;
 +
  font-size: 20px;
 +
  font-family: Corbel;
 +
  font-weight:bold;
 +
  text-align:center;
 +
  position: absolute;
 +
  top:5px;
 +
  left:25px;
 +
}
  
 +
input[type='radio']:hover{
 +
  background: white; 
 +
  color: #FF8800;
 +
  border-color: #FF8800;
 +
}
  
 +
input[type='radio']:checked{
 +
  background: white;
 +
  border-color: #FF8800;
 +
}
 +
.tab {
 +
  margin-left: -20px;
 +
  transition: .3s ease-out;
 +
}
 +
.tab li{
 +
  background: #fff;
 +
  color: black;
 +
  width: 1000px;
 +
  height: 500px;
 +
  display: inline;
 +
  float: left;
 +
  bottom: 0;
 +
  z-index: -1;
 +
}
 +
.tab1:checked ~ ul{
 +
  transform: translateY(0);
 +
}
  
−
<div class="column full_size">
+
.tab2:checked ~ ul{
−
<h2>Entrepreneurship</h2>
+
  transform: translateY(-500px);
 +
}
  
−
<p>
+
.tab3:checked ~ ul{
−
In previous years, iGEM had an entrepreneurship track. Teams were encouraged to build projects and focus around commercializing their work. We have now moved to an award as the best work in this area may come from teams who are not solely focused on entrepreneurship.
+
  transform: translateY(-1000px);
−
</p>
+
}
  
−
<p>The Best Supporting Entrepreneurship award recognizes exceptional effort to build a business case and commercialize an iGEM project. This award is open to all teams to show that entrepreneurship is something all teams can aspire to do with their project. This award can go to an new project, or to a previous project that a team aimed to commercialize. Have you filed a provisional patent on your project/device/process? Have you raised money to build and ship products? Have you pitched your idea to investors and received money? Complete the entrepreneurship section on the 2016 Judging form and tell us what you did. As always in iGEM, the aim is to impress the judges! </p>
+
.tab4:checked ~ ul{
 +
  transform: translateY(-1500px);
 +
}
  
 +
hr1 {
 +
  border: 0;
 +
  width: 80%;
 +
  color: #140731;
 +
  background-color: #140731;
 +
  height: 2px;
 +
}
  
−
<h5>Inspiration</h5>
+
hr {
−
<p>You can look at what other teams did to get some inspiration! <br />
+
  border: 0;
−
Here are a few examples:</p>
+
  width: 80%;
−
<ul>
+
  color: #FF8800;
−
<li><a href="https://2014.igem.org/Team:UCC_Ireland">2014 UCC Ireland</a></li>
+
  background-color: #FF8800;
−
<li><a href="https://2014.igem.org/Team:Imperial">2014 Imperial College London</a></li>
+
  height: 2px;
−
<li><a href="https://2013.igem.org/Team:UCL_E">2013 University College London Entrepreneurship</a></li>
+
}
−
<li><a href="https://2012e.igem.org/wiki/index.php/Team:MIT_E">2012 MIT Entrepreneurship</a></li>
+
.list li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/b/ba/CGU_Taiwan--point.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:-10 5px;
 +
  padding-left:3%;
 +
  background-size:2.5%;
 +
}
 +
 
 +
.end2 {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 100%;
 +
  height: 300%;
 +
  font-family: Corbel;
 +
  z-index:+1;
 +
}
 +
.sitemap {
 +
  background-color:#0D014D;
 +
  position: absolute;
 +
  width: 20%;
 +
  height: 40%;
 +
  font-family: Corbel;
 +
}
 +
.list1 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/5/58/CGU_Taiwan--sitemap.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:10px;
 +
  background-size:9%;
 +
    margin-bottom:-20%;
 +
}
 +
.list2 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:6px;
 +
  background-size:7%;
 +
  margin-bottom:-10%;
 +
}
 +
.list3 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:5%;
 +
  background-size:2%;
 +
  margin-bottom:-10%;
 +
}
 +
</style>
 +
</head>
 +
 
 +
<script>
 +
/* Dynamic top menu positioning
 +
*
 +
*/
 +
var num = 110; //number of pixels before modifying styles
 +
$(window).bind('scroll', function () {
 +
    if ($(window).scrollTop() > num) {
 +
        $('.header-subnav').addClass('fixed1');
 +
    } else {
 +
        $('.header-subnav').removeClass('fixed1');
 +
    }
 +
});
 +
 
 +
var num = 132; //number of pixels before modifying styles
 +
$(window).bind('scroll', function () {
 +
    if ($(window).scrollTop() > num) {
 +
        $('.left').addClass('fixed2');
 +
    } else {
 +
        $('.left').removeClass('fixed2');
 +
    }
 +
});
 +
 
 +
 
 +
//USE SCROLL WHEEL FOR THIS FIDDLE DEMO
 +
 
 +
 
 +
</script>
 +
<script>
 +
var slideIndex = 1;
 +
showDivs(slideIndex);
 +
 
 +
function plusDivs(n) {
 +
  showDivs(slideIndex += n);
 +
}
 +
 
 +
function currentDiv(n) {
 +
  showDivs(slideIndex = n);
 +
}
 +
 
 +
function showDivs(n) {
 +
  var i;
 +
  var x = document.getElementsByClassName("mySlides");
 +
  var dots = document.getElementsByClassName("demo");
 +
  if (n > x.length) {slideIndex = 1}
 +
  if (n < 1) {slideIndex = x.length}
 +
  for (i = 0; i < x.length; i++) {
 +
    x[i].style.display = "none";
 +
  }
 +
  for (i = 0; i < dots.length; i++) {
 +
    dots[i].className = dots[i].className.replace(" w3-border-red", "");
 +
  }
 +
  x[slideIndex-1].style.display = "block";
 +
  dots[slideIndex-1].className += " w3-border-red";
 +
}
 +
</script>
 +
 
 +
<body>
 +
<a name='anchor1'></a>
 +
<div class="top">
 +
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg">
 +
</div>
 +
</div>
 +
 
 +
<header class="top">
 +
<ul class="header-subnav">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan">HOME</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements">ACHIEVEMENTS</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description">PROJECT</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software">MODELING</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices">HUMAN PRACTICES</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team">PEOPLE</a></li>
 +
<li class="dropdown"><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab">INTERLAB</a></li>
 +
<li class="dropdown"><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety">SAFETY</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</a></li>
 
</ul>
 
</ul>
 +
<div class="circle"><img style="position:absolute;z-index:+1;width:90%;height:95%;margin-left:3%;margin-top:2%;" src="https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg"></div>
 +
</header>
  
 +
<div class="mid" style="margin-left:12%;">
 +
<br>
 +
<div style="font-size:60px;color:#9999CC;text-decoration:none;margin-top:30%;">
 +
Entrepreneurship
 +
</div>
 +
<br><br>
 +
 +
<b><font size="6px">Motivation and Goal</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;">
 +
One reason that some severe diseases do not have efficient vaccine is the lack of T cell pathway activation. Due to this finding, leijuvant purpose to directly activate CD4 T cell pathway, and further induced better antibody production. Leijuvant prevent people from infectious diseases that do not have proper drugs, including tuberculosis, malaria and hepatitis C. With leijuvant, hundreds and thousands of people will be saved. Leijuvant has several advantages as a vaccine adjuvant, providing us with a new perspective of protecting ourselves. </div>
 +
<br><br>
  
 +
<b><font size="6px">Business model</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;">
 +
<img src="https://static.igem.org/mediawiki/2016/1/16/EN1.jpeg" width=700px height=400px></img>
 
</div>
 
</div>
 +
<br><br>
  
 +
<b><font size="6px">Marketing</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;">
 +
The number of vaccination per person is increasing while the number of vaccine-preventable diseases is also increasing. This situation accelerates virus recombination and evolution, thus, new approach is necessary for vaccine industry. Furthermore, therapeutic vaccines that target specific antigens develop rapidly in oncology and immune diseases, heralding a new vaccine market.<br>
 +
In our own survey, we made a questionnaire for public to figure out the demands of indirectly customers. For integrated marketing, we also interviewed with several experts of both basic research, industries and the hospital system (<a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey#anchor3">read more</a>). In the future, we will collect information from our main customers in a large scale and further analyze the data to solid our business model.<br>
 +
</div>
 +
<br><br>
  
 +
<b><font size="6px">Law and regulation </font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;">
 +
FDA is the main administrative organ managing pharmaceutical products in Taiwan, following the acts of GMP and ISO. The environmental impact, safety, and production issues are also under our concern. Detail information is written in our integrated HP wiki page.</div>
 +
<br><br>
  
 +
<b><font size="6px">Progress</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;"><br>
 +
<img src="https://static.igem.org/mediawiki/2016/4/4d/EN2.jpeg" width=850px height=400px></img><br><br>
 +
We have proven that Leishmania could activate CD4 T cell pathway inducing efficient humoral immune response. In Further study, we will change the well-established OVA protein into our target protein from hepatitis C virus, plasmodium and tuberculosis. Since Leishmania can also be used as treatment drugs toward cytotoxic pathway, it is possible that generate both therapeutic and prophylactic drugs toward Leishmania system. Leijuvant targets diseases that are under rare medical conditions which correspond to the applicant qualifications of orphan drug. In order to benefit patients suffering from diseases without efficient drugs, FDA fastens the process of orphan drug development clinical trial phase 3, accelerating the procedure of leijuvant launched on the market and reducing the cost. The orphan drug application will be summited after preclinical trial is completed. Patent application will also be submitted before clinical trial start. In our blue plan, we will finish preclinical trial and clinical trial in 7 and 4 years respectively and launch leijuvant in 2029.
 +
<br>
 +
</div>
 +
<br><br>
  
 +
<b><font size="6px">Leijuvant production (mimic real-world conditions)</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;"><br>
 +
<img src="https://static.igem.org/mediawiki/2016/0/0a/Leijuvant_%E6%B5%81%E7%A8%8B%E5%9C%96.png" width=850px height=150px></img><br><br>
 +
Suppose our target antigen is an unknown virus. First, enter the antigen sequence into the MHC peptide prediction system, McHug, to analysis the MHC binding affinity and other basic features. And get the antigen sequence of your interest. Construct the sequence into shuttle vector to maximize the production of the antigen. Transfect the vectors into Leishmania through electroporation. Through drug selection we can select the successfully transfected Leishmania and mass culture it. Then we will use double-photo inactivation system to completely remove its infectiousness. Repeat the same process and we can design and produce different antigen specific leijuvant.<br>
 +
</div>
 +
<br><br>
 +
 +
<b><font size="6px">Sponsor</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-right:10%;">
 +
We will solicit cooperation with pharmaceutical companies that produce vaccines and adjuvants, such as GSK, Merck, Novartis, Pfizer and Sanofi. Project could be improved and process more smoothly toward discussion that combine both scientific and business perception.
 +
</div>
 +
<br><br>
 +
</div>
 +
 +
 +
 +
 +
<div class="end2" style="margin-top:220%;">
 +
<br>
 +
<ul class="list3" class="margin-left:1%;margin-top:2%;">
 +
<li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li>
 +
</ul>
 +
<br>
 +
<div class="sitemap" style="margin-left:5%;">
 +
<br>
 +
<b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br>
 +
<br><br>
 +
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:40%;height:70%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg">
 +
</div>
 +
<br>
 +
 +
<div class="sitemap" style="margin-left:22%;margin-top:-1%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:40%;margin-top:-2%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a>
 +
<br><br>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;">
 +
<ul class="list1" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;">
 +
<li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a>
 +
</ul>
 +
</ul>
 +
<ul class="list1" class="margin-left:1%;margin-top:-10%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:-5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
</div>
  
  
 +
</body>
 
</html>
 
</html>

Latest revision as of 06:30, 2 December 2016


Entrepreneurship


Motivation and Goal
One reason that some severe diseases do not have efficient vaccine is the lack of T cell pathway activation. Due to this finding, leijuvant purpose to directly activate CD4 T cell pathway, and further induced better antibody production. Leijuvant prevent people from infectious diseases that do not have proper drugs, including tuberculosis, malaria and hepatitis C. With leijuvant, hundreds and thousands of people will be saved. Leijuvant has several advantages as a vaccine adjuvant, providing us with a new perspective of protecting ourselves.


Business model


Marketing
The number of vaccination per person is increasing while the number of vaccine-preventable diseases is also increasing. This situation accelerates virus recombination and evolution, thus, new approach is necessary for vaccine industry. Furthermore, therapeutic vaccines that target specific antigens develop rapidly in oncology and immune diseases, heralding a new vaccine market.
In our own survey, we made a questionnaire for public to figure out the demands of indirectly customers. For integrated marketing, we also interviewed with several experts of both basic research, industries and the hospital system (read more). In the future, we will collect information from our main customers in a large scale and further analyze the data to solid our business model.


Law and regulation
FDA is the main administrative organ managing pharmaceutical products in Taiwan, following the acts of GMP and ISO. The environmental impact, safety, and production issues are also under our concern. Detail information is written in our integrated HP wiki page.


Progress



We have proven that Leishmania could activate CD4 T cell pathway inducing efficient humoral immune response. In Further study, we will change the well-established OVA protein into our target protein from hepatitis C virus, plasmodium and tuberculosis. Since Leishmania can also be used as treatment drugs toward cytotoxic pathway, it is possible that generate both therapeutic and prophylactic drugs toward Leishmania system. Leijuvant targets diseases that are under rare medical conditions which correspond to the applicant qualifications of orphan drug. In order to benefit patients suffering from diseases without efficient drugs, FDA fastens the process of orphan drug development clinical trial phase 3, accelerating the procedure of leijuvant launched on the market and reducing the cost. The orphan drug application will be summited after preclinical trial is completed. Patent application will also be submitted before clinical trial start. In our blue plan, we will finish preclinical trial and clinical trial in 7 and 4 years respectively and launch leijuvant in 2029.


Leijuvant production (mimic real-world conditions)



Suppose our target antigen is an unknown virus. First, enter the antigen sequence into the MHC peptide prediction system, McHug, to analysis the MHC binding affinity and other basic features. And get the antigen sequence of your interest. Construct the sequence into shuttle vector to maximize the production of the antigen. Transfect the vectors into Leishmania through electroporation. Through drug selection we can select the successfully transfected Leishmania and mass culture it. Then we will use double-photo inactivation system to completely remove its infectiousness. Repeat the same process and we can design and produce different antigen specific leijuvant.


Sponsor
We will solicit cooperation with pharmaceutical companies that produce vaccines and adjuvants, such as GSK, Merck, Novartis, Pfizer and Sanofi. Project could be improved and process more smoothly toward discussion that combine both scientific and business perception.





SITE MAP